This review discusses the limitations of current therapies and highlights novel targeted agents for recurrent head and neck cancer, suggesting promising clinical trials.
Systemic therapy remains the cornerstone of treatment for recurrent and metastatic (R/M) head and neck squamous cell cancers (HNSCC). However, there is a dearth of effective treatments beyond platinum combinations, anti-programmed death-1 (PD-1) agents and the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab. Recent years have seen several exciting new agents being tested in clinical trials. These are designed to target alternate oncogenic signaling pathways and have novel mechanistic compositions, including bi-specific antibodies and antibody-drug conjugates. This review will delve into the clinical limitations of currently approved systemic therapies, explore newer agents in development and highlight ongoing clinical trials using targeted therapies in this disease.
No takes yet. Share an insight, caveat, or question.
Abouelkheer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: